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Efficacy of antidepressants over placebo is similar in
two-armed versus three-armed or more-armed randomized
placebo-controlled trials
Yusuke Ogawaa, Toshi A. Furukawaa,b, Nozomi Takeshimaa, Yu Hayasakaa,
Lauren Z. Atkinsond,e, Shiro Tanakac, Andrea Ciprianie,f and Georgia Salantig
Previous studies have reported that effect sizes of
antidepressants were larger in two-armed than in three-
armed or more-armed (multiarmed) randomized trials,
where the probability of being allocated to placebo is lower.
However, these studies have not taken into account the
publication bias, differences among antidepressants, or
covariance in multiarmed studies, or examined sponsorship
bias. We searched published and unpublished randomized-
controlled trials that compared placebo with 21
antidepressants for the acute treatment of major
depression in adults. We calculated the ratio of odds ratios
(ROR) of drug response over placebo in two-armed versus
multiarmed trials for each antidepressant, and then
synthesized RORs across all the included antidepressants
using the multivariate meta-analysis. A random-effects
model was used throughout. Two hundred and fifty-eight
trials (66 two-armed and 192 multiarmed trials; 80 454
patients; 43.0% with unpublished data) were included in the
present analyses. The pooled ROR for response of two-
armed trials over multiarmed trials was 1.09 (95%
confidence interval: 0.96–1.24). The ROR did not materially
change between types of antidepressants, publication year,
or sponsorship. The differences between two-armed versus
multiarmed studies were much smaller than were
suggested in previous studies and were not significant. Int
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Introduction
Pharmacotherapy is the mainstay in today’s treatment of
major depression, and hundreds of randomized-
controlled trials (RCTs) of various antidepressants have
been conducted so far to examine their efficacy
(Furukawa et al., 2016). Randomized, double-blind,
placebo-controlled trials are required by regulatory
agencies worldwide to obtain their approval for use with
humans, and are considered to be the gold standard for
the evaluation of efficacy of antidepressants.
However, overestimation of drug efficacy in traditional
placebo-controlled trials has been suggested when effect
sizes (ESs) were compared between two-armed and
three-armed RCTs. Although the efficacy of the same
antidepressant over placebo should not be different
whether compared head to head against placebo or
compared against another active drug along with placebo,
the magnitude of the ES for antidepressants in three-
armed RCTs was much smaller than those obtained in
previous analyses that included two-armed trials
(Greenberg et al., 1992). These authors ascribed this
difference to the greater possibility of unblinding in two-
armed versus multiarmed studies. Blinding may indeed
be difficult to maintain in studies of psychotropic drugs
because these drugs have characteristic side effects
(Margraf et al., 1991; Even et al., 2000; Moncrieff et al.,
2004). When double-blindness is breached, drug efficacy
over placebo would probably be overestimated (Leucht
et al., 2009).
Some reports have also suggested that antidepressant–placebo
difference was associated negatively with the number of
treatment arms (Khan et al., 2004; Papakostas and Fava, 2009;
Sinyor et al., 2010). These authors implicated the role of
expectancy that would lead to greater drug–placebo difference
when the expectancy of receiving placebo is high.
All the above studies, however, have several problems.
First, previous meta-analyses have unfortunately often
been subject to publication bias. Analysis of the trial data
submitted to Food and Drug Administration as a
requirement of their submission process showed that
only half of the phase II or III placebo-controlled trials
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had positive results, and most of the ‘negative’ trials had
not been published (Turner et al., 2008). The reported
difference in ESs between two-armed and three-armed
trials may be because of greater publication bias among
the former as the latter RCTs may be more likely to be
published even when there is no significant difference
between the antidepressant of interest and placebo
because the publication can focus on the comparison
between the two active drugs. Second, previous studies
have generally assumed that ESs of antidepressants are
the same among all antidepressants. However, it has
been reported that they may be markedly different
(Cipriani et al., 2009). Therefore, intervention effects
should be examined and compared for each anti-
depressant separately. Third, it has been shown that an
antidepressant appeared to be more effective when it was
the new agent rather than the comparator, suggesting
evidence of the so-called ‘novelty effect’ (Barbui et al.,
2004; Salanti et al., 2010). The studies cited above
(Greenberg et al., 1992; Khan et al., 2004; Papakostas and
Fava, 2009; Sinyor et al., 2010) have not taken this factor
into account so that the apparently larger ES reported in
two-armed studies might be because of the ‘novelty
effect’ of the agent, which is more likely to be studied in
two-armed rather than multiarmed trials when the agent
is ‘new’ and when the trial is sponsored by the manu-
facturer of the drug.
The aim of the present study is therefore to compare the
odds ratios (ORs) of antidepressants over placebo when
examined in two-armed versus three-armed or more-
armed (heretofore termed multiarmed) trials while taking
into account possible differences among different anti-
depressants on the basis of a dataset compiled with as
little publication bias as possible.
Methods
This is a secondary analysis of published and unpub-
lished data from RCTs of antidepressants that were col-
lected for GRISELDA, a multinational project to
conduct network meta-analyses of 21 new and old anti-
depressants for adult major depression. The details of the
study methodology have been published (Furukawa
et al., 2016) and thus, here, we present its summary as
relevant to this secondary analysis.
Criteria for considering studies for this review
All double-blind RCTs that compared placebo with the fol-
lowing selected first-generation and second-generation anti-
depressants as monotherapy for the acute-phase treatment
of depression were included: agomelatine, amitriptyline,
bupropion, citalopram, clomipramine, desvenlafaxine, dulox-
etine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran,
milnacipran, mirtazapine, nefazodone, paroxetine, reboxetine,
sertraline, trazodone, venlafaxine, vilazodone, and vortiox-
etine. We included RCTs with patients aged 18 years or
older, of both sexes, and with a primary diagnosis of unipolar
major depression, diagnosed according to any standard oper-
ationalized diagnostic criteria.
Search methods for identification of studies
We searched Cochrane CENTRAL, CINAHL, EMBASE,
LiLACS, MEDLINE, PSYCINFO, trial databases of the
drug-approving agencies, trial registers, and homepages of
pharmaceutical companies that market the included drugs
up to 8 January 2016. The National Institute for Health
and Care Excellence (UK) and the Institut für Qualität und
Wirtschaftlichkeit im Gesundheitswesen (Germany) were
also contacted. The reference lists of the identified RCTs
and recent systematic reviews were checked. No language
restriction was applied.
Data collection
Response to the treatment was defined as a reduction of
at least 50% from baseline on the total score on the
Hamilton Rating Scale for Depression (Hamilton, 1960),
the Montgomery–Asberg Depression Rating Scale
(Montgomery and Asberg, 1979), or any other validated
depression scale at the end of acute-phase treatment. In
the present review, acute treatment was defined as an
8-week treatment (Bauer et al., 2002). If 8-week data
were not available, we used data ranging between 4 and
12 weeks. When the number of responders was not
reported, but the baseline mean and endpoint mean and
SD of the depression rating scales were provided, we
calculated the number of responding patients by using a
validated imputation method (Furukawa et al., 2005).
Two researchers independently examined the titles and
abstracts of all reports obtained through the search
strategy. Full articles of all the potentially eligible studies
were then obtained and inspected by two review authors
to identify trials that fulfilled the review criteria. Data
from each study were extracted into a structured data
abstraction form independently by two researchers. The
risk of bias was assessed for each included study using
the Cochrane Collaboration ‘risk of bias’ tool (Higgins
and Green, 2011) by two independent researchers. Any
disagreement was resolved through discussion or in
consultation with a third member of the review team. On
the basis of assessments of risks of bias for each domain,
we quantified the overall risk of bias for each study as low
risk if none of the domains was rated at high risk and
three or fewer domains at unclear risk; as moderate risk if
one domain was rated at high risk or none rated at high
risk but four or more at unclear risk; or as high risk for all
other cases.
Statistical analysis
For each antidepressant, we first estimated the overall ORs
of response between the antidepressant and placebo by
synthesizing ORs from all two-armed or multiarmed com-
parisons using the random-effects model. We next estimated
the ratio of odds ratios (RORs) and their variance of
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two-armed versus multiarmed trials for each antidepressant,
and finally meta-analytically synthesized RORs across all the
included antidepressants using the random-effects model.
A random-effects model was used throughout because of
possible clinical heterogeneity across the included trials
because of differences in clinical populations, drugs, and drug
dosages. A summary ROR larger than 1 would mean that
two-armed RCTs show larger intervention effects compared
with placebo than multiarmed trials do. Because two or more
antidepressants were involved in multiarmed studies, the
summary RORs were correlated (the placebo arm is the same
in two estimates in the same trials in common) and we need
to take account of these correlations; for example, the ROR
for placebo versus agomelatine and the ROR for placebo
versus paroxetine will be dependent because they include
data from the same placebo arms in placebo versus agome-
latine versus paroxetine trials. The synthesis of these RORs
was therefore performed using a multivariate meta-analysis
routine in R (rma.mv in the metafor package in R Core
Team; R Foundation for Statistical Computing, Vienna,
Austria) after specifying the entire variance–covariance
matrix (Appendix). We used Review Manager 5.3 (Nordic
Cochrane Centre, Cochrane Collaboration, Copenhagen,
Denmark), Stata 14 (StataCorp LP, College Station, Texas,
USA), and R to carry out the analyses.
We started the assessment of heterogeneity by visual
inspection of the forest plots. We also calculated I2 sta-
tistics (Higgins and Green, 2011) and analyzed them on
the basis of the Cochrane Handbook’s recommendations
(I2 values of 0–40%: might not be important; 30–60%:
may represent moderate heterogeneity; 50–90%: may
represent substantial heterogeneity; 75–100%: consider-
able heterogeneity).
Sensitivity analyses
To ascertain the robustness of our findings, we carried
out the following sensitivity analyses:
(1) By excluding studies at high risk of bias.
(2) By excluding studies where primary outcomes were
imputed rather than reported.
(3) By using the fixed-effect model instead of the
random-effects model.
Subgroup analyses
We had a-priori planned to carry out the following sub-
group analyses:
(1) Numbers of arms in the multiarmed trials separately
(three-armed, four-armed, and five-armed).
(2) Type of antidepressants (tricyclic antidepressants
versus new-generation antidepressants).
(3) Publication year [those published until the date of
search, until 1990 (Greenberg et al., 1992), and
unpublished].
(4) Sponsorship (sponsored drug arms and nonsponsored
drug arms in multiarmed trials).
Results
Characteristics of the randomized-controlled trials
included
Three hundred and four placebo-controlled trials were
identified by the electronic search. However, efficacy data
were missing in 35 studies. There were no RCTs com-
paring milnacipran or clomipramine against placebo pro-
viding efficacy data. All placebo-controlled RCTs for
fluvoxamine were three-armed or more-armed. Therefore,
we could not calculate ROR for these three anti-
depressants. Altogether, 258 RCTs (80 454 patients) were
finally included in the present analyses (Fig. 1). Table 1
presents detailed characteristics for two-armed and multi-
armed RCTs. Among the 258 RCTs included in this study,
66 (25.6%) were two-armed and 192 were multiarmed,
including, 139 (53.9%) three-armed RCTs, 43 (16.7%)
four-armed RCTs, and 10 (3.9%) five-armed RCTs. The
median sample size of each active arm was 98.5 (first
quartile, 43.5; third quartile, 158) for two-armed trials and
118.5 (first quartile, 66; third quartile, 157) for multiarmed
trials. The median number of studies per antidepressant
was 13.5 (range: 5–46). Figure 2 summarizes the risk of bias
of the studies included. All in all, 46 studies were rated as
being at low risk of bias, 214 at moderate risk of bias, and
64 at high risk of bias.
Differences in effect size between two-armed and
multiarmed randomized-controlled trials
Pooled response rates for the two treatment groups (anti-
depressants and placebo) were 45.8 and 31.4% in two-
armed RCTs and 49.7 and 37.6% in multiarmed RCTs,
respectively (Fig. 3). There was no significant difference
between two-armed and multiarmed RCTs in the OR of
response between antidepressant and placebo [pooled
ROR: 1.09; 95% confidence interval (CI): 0.96–1.24]
(Fig. 4). The antidepressants are listed in the order of their
approval. There was small to moderate heterogeneity in
RORs across antidepressants (I2= 39.6%; 95% CI:
0.0–65.6%). Because taking account of the covariance had
little influence on the estimated ROR (the simple pooled
ROR was 1.09 (I2= 38.6%; 95% CI: 0.96–1.24), the fol-
lowing sensitivity and subgroup analyses were carried out
without accounting for the covariances because of multi-
armed studies.
Sensitivity analyses
After exclusion of studies at high risk of bias, the ROR
was 1.06 (I2= 34%; 95% CI: 0.92–1.21). After exclusion of
studies that imputed the number of responders, ROR
was 1.06 (I2= 45%; 95% CI: 0.90–1.25). Using the fixed-
effect model instead of the random-effects model, ROR
was 1.09 (I2= 38.6%; 95% CI: 0.99–1.19).
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Subgroup analyses
The pooled ROR was 1.12 (I2= 22%; 95% CI: 0.99–1.26)
for two-armed versus three-armed RCTs, 1.03 (I2= 33%;
95% CI: 0.87–1.22) for two-armed versus four-armed
RCTs, and 1.10 (I2= 36%; 95% CI: 0.84–1.43) for two-
armed versus five-armed RCTs. ROR of tricyclic anti-
depressant versus placebo was 2.00 (95% CI: 0.39–10.32)
and that of new-generation antidepressants versus pla-
cebo was 1.09 (I2= 41%; 95% CI: 0.96–1.24). ROR was
1.08 (I2= 40%; 95% CI: 0.93–1.25) on the basis of the
studies published up to the date of search (i.e. by
excluding all unpublished studies), 2.34 (I2= 0%; 95%
CI: 0.57–9.66) on the basis of the studies up to 1990, and
1.19 (I2= 0%; 95% CI: 0.93–1.51) on the basis of the
studies that were not published. Similar results were
obtained when the drugs in multiarmed studies were
marketed by the sponsor of the drug (ROR= 1.09;
I2= 32%; 95% CI: 0.96–1.25) or when they were not
(ROR= 1.07; I2= 37%; 95% CI: 0.90–1.28).
Discussion
The differences between the two-armed versus multi-
armed studies were much smaller than those found in
previous studies, and were not statistically significant.
For this study we used the data of the largest systematic
review of antidepressants including 66 two-armed RCTs
and 192 multiarmed RCTs, corresponding to 80 454
patients. The results of subgroup and sensitivity ana-
lyses did not alter this conclusion. RORs appeared larger
for tricyclic antidepressants and for studies before 1990,
but were not statistically significant either.
The differences between the previous studies and the
present study may be explained as follows: first, the
publication bias in our dataset is reduced as we could find
unpublished information for 43.0% of the included stu-
dies through contacts with pharmaceutical companies and
regulatory agencies. We could thus include the largest
number of trials to date (258 trials), in comparison with 22
(Greenberg et al., 1992), 52 (Khan et al., 2004), 90 (Sinyor
et al., 2010), or 182 (Papakostas and Fava, 2009). Second,
we used the random-effects model, which produces
wider 95% CI than the fixed-effect model in the pre-
sence of heterogeneity. Although the overall the ORs
tended to be higher in two-armed studies than multi-
armed ones, the differences did not reach statistical
Fig. 1
Excluded (n=122)
• Not fulfilling eligibility
criteria (n=102)
• Unable to check eligibility
(n=4)
• Duplicate publication
(n=16)
Records identified
through database
searching (n=24,200)
Additional unpublished records
identified through other sources
(industry websites, trial registries,*
contacting authors) (n=4,030)
Unpublished studies
selected (n = 86)
Ten reviews hand
searched (n=311)
& personal
communication (n=11)
Published studies
selected (n=15)
Excluded by checking title
and abstract (n=23,656)
Studies selected for
inclusion (n=422)
Full-text articles assessed
for eligibility (n=544)
Full-text studies completed and
probably eligible (n=121)
Excluded (n=35)
• no results available
Excluded (n=307)
• Studies already
included or
identified
Excluded (n=3,909)
258 STUDIES SELECTED:
66  Two-armed RCTs
192  Multi-armed RCTs
46 studies excluded:
35 without number of responders or
participants
11 fluvoxamine RCTs
(only three or more-armed RCTs)
304 potentially relevant placebo controlled
studies identified from the literature search
Flow diagram. RCT, randomized-controlled trial.
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significance. We believe that our study had performed a
more methodologically rigorous synthesis by estimating
the ROR for each antidepressant, and then meta-
analytically pooling all the RORs of the included anti-
depressants, instead of assuming a common efficacy for
all the antidepressants included. A sensitivity analysis
using the fixed-effect model instead of the random-effects
model confirmed the primary findings. Third, the novelty
effect (Barbui et al., 2004; Salanti et al., 2010) did not
appear to be at play to explain the possible differences
between two-armed versus multiarmed studies because
our subgroup analysis found little difference when the
drugs in multiarmed studies were marketed by the sponsor
of the drug or when they were not.
Table 1 Characteristics of two-armed and three-armed or more-
armed randomized-controlled trials
Two-armed
RCTs (n=66)
Multiarmed RCTs
(n=192)
Number of RCTs [n (%)] Two-armed: 66
(25.6)
Three-armed: 139
(53.9)
Four-armed: 43
(16.7)
Five-armed: 10 (3.9)
Sample size per active arm [median
(interquartile range)]
98.5 (43.5,
158)
118.5 (66, 157)
Antidepressants examined (n of trials, n of participants)
Amitriptyline 2, 176 27, 3112
Trazodone 2, 794 8, 517
Fluoxetine 6, 1018 33, 7431
Bupropion 8, 1531 16, 4144
Sertraline 5, 1374 14, 2775
Paroxetine 8, 734 38, 8899
Venlafaxine 2, 290 20, 4895
Nefazodone 1, 120 8, 1242
Mirtazapine 3, 297 10, 1450
Reboxetine 4, 368 7, 2244
Citalopram 2, 358 11, 3428
Escitalopram 3, 956 16, 5133
Duloxetine 5, 1599 16, 4673
Agomelatine 5, 1112 8, 3061
Desvenlavaxine 2, 876 7, 3503
Vilazodone 4, 1629 4, 1841
Levomilnacipran 3, 1362 2, 1292
Vortioxetine 1, 600 13, 5620
Year of publication [n (%)]
1979–1990 7 (11) 24 (13)
1991–2000 17 (26) 45 (23)
2001–2016 29 (44) 79 (41)
Unpublished 13 (20) 44 (23)
RCT, randomized-controlled trial.
Fig. 2
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presented as percentages across all included studies.
Fig. 3
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Antidepressant and placebo response rates.
Fig. 4
amitriptyline 2.00 [0.39, 10.34]
trazodone 0.88 [0.36, 2.14]
fluoxetine 1.34 [0.98, 1.83]
bupropion 1.33 [0.93, 1.90]
sertraline 1.05 [0.77, 1.44]
paroxetine 1.13 [0.81, 1.57]
venlafaxine 1.72 [1.04, 2.84]
nefazodone 1.43 [0.65, 3.15]
mirtazapine 0.94 [0.53, 1.67]
reboxetine 1.65 [0.59, 4.65]
citalopram 0.83 [0.51, 1.33]
escitalopram 0.95 [0.70, 1.29]
duloxetine 0.98 [0.72, 1.34]
agomelatine 1.25 [0.85, 1.84]
desvenlavaxine 1.15 [0.84, 1.57]
vilazodone 1.44 [0.98, 2.12]
levomilnacipran 1.04 [0.70, 1.55]
vortioxetine 0.52 [0.36, 0.76]
Total 1.09 [0.96, 1.24]
ROR[95% CI] ROR
0.14 10.37 2.72 20.097.39
Ratio of odds ratios (ROR) between two-armed and multiarmed
randomized-controlled trials (RCTs). The antidepressants are listed in
the order of their approval. CI, confidence interval.
70 International Clinical Psychopharmacology 2018, Vol 33 No 2
Copyright r 2018 Wolters Kluwer Health, Inc. All rights reserved.
Sinyor et al. (2010) showed that the response rate for
placebo was significantly higher in three-armed studies
than in two-armed studies; thus, it is difficult to show the
superiority of drugs in studies with more active treatment
arms. Although the placebo response rate in multiarmed
studies was indeed larger than that in two-armed studies
in our dataset, so was the response rate on antidepressant
drugs (Fig. 3), resulting in the similar relative efficacy of
drugs over placebo in both types of trials (Fig. 4).
Our study has some limitations. We could not consider
other trial and patient features that may have an impact
on intervention effects, such as the difference in rating
scales, countries and cultures, the proportion of melan-
cholic depression, depression severity, and duration of
the illness or the number of depressive episodes.
Systematic differences in these characteristics between
two-armed versus multiarmed studies might have played
a role, but we would need individual participant data to
examine such effect modifiers. Moreover, given that the
field of antidepressant trials in the past has been prone to
publication bias, we cannot completely rule out the
possibility that some studies are still missing.
In summary, we found that intervention effects were not
significantly different between two-armed and multi-
armed RCTs. Our original hypotheses that possible
breach of the double-blinding in antidepressant clinical
trials or the lower expectancy for the active drug in two-
armed rather than multiarmed trials would lead to over-
estimation of antidepressant efficacy was not borne out.
Our results were different from those in the previous
studies possibly because we appropriately took into
account differences among different antidepressants
through the random-effects model and also because we
could minimize the publication bias.
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Appendix: multivariate meta-regression to
synthesize RORs
Consider that there are nA multiarm trials (more than two
arms) that involve drug A and nB multiarm trials that
involve drug B. There are also n multi-arm trials that
involve both drugs A and B; these studies contribute
correlated data to the estimation of ORAVP and ORBVP.
Consequently, the two ratios of odds ratios
RORA¼ OR
AvP in two-armed studies
ORAvPin nA multiarmed studies
;
RORB¼ OR
BvP in two-armed studies
ORBvP in nB multiarmed studies
;
are correlated because their denominators are correlated.
We need to estimate the covariance c(log RORA, log
RORB). Assuming a fixed-effects model and that the study
weights are known and fixed, it is easy to show that:
cðlogRORA; logRORBÞ¼
cðlogORAVP inmultiarm studies;
logORAVP inmultiarm studiesÞ:
Consequently:
cðlogRORA; logRORBÞ¼
Pn
i
wAi w
B
i
1
Si
þ 1Fi
 
PnA
i w
A
i
PnB
i w
B
i
;
where wAi is the inverse of the variance of log OR
AvP in
the multiarm study i; wBi is the inverse of the variance of
log ORBvP in the multiarm study i; Si is the number of
successes in the placebo arm in the multiarm study i; Fi is
the number of failures in the placebo arm in the multiarm
study i.
The synthesis of the RORs was performed using a mul-
tivariate meta-analysis routine in R (rma.mv in the metafor
package) after specifying the entire variance–covariance
matrix.
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